Management of feline diabetes mellitus: update and challenges by Caparrós Vallcorba, Cristina & Universitat Autònoma de Barcelona. Facultat de Veterinària
Management of feline diabetes mellitus: 
update and challenges
Cristina Caparrós Vallcorba
June 2017
This study intends to perform an updated revision of the management
of feline diabetes mellitus (DM):
• Focusing in the importance of the nutritional management to
control blood glucose (BG) values
• Evaluating the different insulin types currently available on the
market and comparing its short and long term efficacy
• Emphasizing the importance of the intensive patient monitoring
and the difficulties in the real clinical practice
DM is one of the most frequent endocrinal diseases in cats
(prevalence of 0.2-1%). It is defined as a persistent hyperglycaemia
caused by a relative or absolute insulin deficiency. The 80% of the
cats suffer type 2 DM, characterized by the presence of insulin
resistance and β pancreatic cell dysfunction. Despite the fact that is an
easily diagnosed disease, its management display important
challenges and require the active participation of the owner to
accomplish an intensive BG control, especially if the remission of the
disease is sought.
The odds of remission are between 33-100% with the combination of
insulin therapy and nutritional management. The objective will be to
reduce the high post-prandial glycemia of cats. The different options
for the diet are:
Another important consideration is to feed the animal with a wet-food
diet instead of a dry-food diet:
• Lower CH content
• Lower energy density
• Highest water content
Table 1. Relevant data of different insulin types 1
The different duration between insulin types lead to diverse mean 12h
BG concentrations (Figure 1). Lente insulin shorter action induce
periods of hyperglycemia during the day and the progression of disease.
Figure 1. Mean BG concentration curve of different insulin types 2
Glargina and Detemir have a consistent profile activity instead of acute
peak activity of Lente insulin and PZI, providing lower probability of
clinical hypoglycaemia and a tight BG control.
An intensive treatment with Glargina or Detemir including correct
nutritional management achieves greater remission rates than Lente
insulin or PZI.
AIMS
INTRODUCTION
NUTRITIONAL MANAGEMENT
• Although is preferable to fed with a low-CH/high-protein diet, patients should be assessed individually in nutritional management as there is no
proper diet for all of them, especially in cases of obesity and chronic kidney disease.
• Most recent experimental studies reveal that long-acting insulins, glargina and detemir particularly, are the best option for the treatment during first
months after diagnosis. Administrating the doses every 12 h achieves smaller daily BG fluctuations and greater remission rates.
• Further experimental studies on detemir action are needed. Although different sources affirm that detemir and glargine have very similar
therapeutic results, there are certain findings indicating that detemir could have longer duration than glargine.
• It is necessary to improve home monitoring tools and involve the owner for tight control of the disease, which increases remission possibilities.
Low-carbohydrate (CH) / High-protein diet
 Stabilize glucose metabolism
 Reduce or remove the needs of exogenous
insulin
 Avoiding loss of muscle mass
 To prevent the development of hepatic lipidosis
≤12% CH
(of total calories)
>40% protein
(of total calories)
High-fiber diet
 Delay or decrease carbohydrate absorption
 Contains half caloric density comparing with
low CH diets (with greater fat content)
13% fiber
(of dry matter)
Low-protein / Low phosphorus diet
 Extend survival time and improve patient life 
quality
22% protein
(of total calories)
1st option
Obesity
Chronic Kidney Disease
Achieve greater feeling of satiety
that favours los of weight
INSULIN TREATMENT
Insulin types
Peak activity
(post-injection)
Duration of 
effect
Frequency of 
administration
Medium-acting
2-8 h 8-10 h q8-12 h 
Lente insulin
Long-acting
2-6 h 13-24 h q12h
Protamine zinc insulin (PZI)
Glargine
12-14 h
12 a >24h 
(10-16h)
q12h
Detemir
Figure 2. Cumulative proportion of cats going into remission 2
Intensive monitoring is necessary to apply the correct changes in
insulin dose, which should be based in clinical signs, BG values and the
insulin action duration.
In large term, the information provided by the owner will be essential to
indicate the disease development. The most important parameters are
daily water intake (20 ml/kg/day in a good control), urine production,
body weight, urine glucose and BG as often as possible.
MONITORING
Insulin types Initial dose BG values Maximum dose change frequency
Medium-acting 0.25-0.5 UI/kg 
q12h
Nadir Every 3-5 days
Long-acting Pre-insulin Every 5-7 days
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CONCLUSIONS
